Postirradiated neuroendocrine carcinoma of the sinonasal tract.
OBJECTIVE
Neuroendocrine carcinoma (NEC) of the sinonasal tract is rare. In this present study, we report our treatment experience with sinonasal NEC.


METHODS
Retrospective case series.


METHODS
A retrospective review of the clinical outcomes and pathology of 18 patients with NEC arising from the sinonasal region.


RESULTS
Ten tumors were primary NEC without previous radiation, and eight tumors were postirradiated NEC occurring within the radiation field for previous nasopharyngeal carcinoma in six patients and tonsillar lymphoma in one and neck metastasis of unknown primary origin in one, with an interval between previous radiotherapy and diagnosis of NEC from 82 to 385 months, with a mean of 197 months. Fifteen tumors were small cell carcinoma, two were atypical carcinoid, and one was typical carcinoid tumor. Fifteen patients underwent surgery with/without postoperative adjuvant chemoradiotherapy. Three patients received induction chemotherapy or primary radiotherapy with further definitive treatment. The 5-year disease-free and overall survival rates of all 18 patients were 56.1% and 62.2%, respectively. In comparing primary NEC with postirradiated NEC, they were similar in age, sex distribution, stage, pathology, and treatment, and the 5-year overall survival rates were 70% and 62.5%, respectively.


CONCLUSIONS
In this series, postirradiated NEC is common, which may be the result of there being a large number of long-term nasopharyngeal carcinoma survivors. The prognoses of postirradiated NEC and primary NEC appear to be similar despite the relatively short follow-up period in the postirradiated NEC group.
Wang
Cheng-Ping
CP
Institute of Biomedical Engineering, College of Medicine, National Taiwan University, Taipei, Taiwan.
Hsieh
Chia-Ying
CY
Chang
Yih-Leong
YL
Lou
Pei-Jen
PJ
Yang
Tsung-Lin
TL
Ting
Lai-Lei
LL
Ko
Jenq-Yuh
JY
D000328:Adult; D000368:Aged; D018278:Carcinoma, Neuroendocrine / Q000473:pathology* / Q000532:radiotherapy*; D018288:Carcinoma, Small Cell / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D006801:Humans; D008223:Lymphoma / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008441:Maxillary Neoplasms / Q000556:secondary / Q000601:surgery; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D014067:Tonsillar Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery